Litcius/Paper detail

Adenosine A <sub>2A</sub> receptor blockade prevents cisplatin-induced impairments in neurogenesis and cognitive function

Alfredo Oliveros, Ki Hyun Yoo, Mohammad Abdur Rashid, Ana Corujo-Ramirez, Benjamin Hur, Jaeyun Sung, Yuanhang Liu, John R. Hawse, Doo‐Sup Choi, Detlev Boison, Mi‐Hyeon Jang

2022Proceedings of the National Academy of Sciences31 citationsDOIOpen Access PDF

Abstract

Chemotherapy-induced cognitive impairment (CICI) has emerged as a significant medical problem without therapeutic options. Using the platinum-based chemotherapy cisplatin to model CICI, we revealed robust elevations in the adenosine A 2A receptor (A 2A R) and its downstream effectors, cAMP and CREB, by cisplatin in the adult mouse hippocampus, a critical brain structure for learning and memory. Notably, A 2A R inhibition by the Food and Drug Administration–approved A 2A R antagonist KW-6002 prevented cisplatin-induced impairments in neural progenitor proliferation and dendrite morphogenesis of adult-born neurons, while improving memory and anxiety-like behavior, without affecting tumor growth or cisplatin’s antitumor activity. Collectively, our study identifies A 2A R signaling as a key pathway that can be therapeutically targeted to prevent cisplatin-induced cognitive impairments.

Topics & Concepts

NeurogenesisCisplatinCREBHippocampusNeuroscienceAdenosinePharmacologyNeural stem cellMedicineCancer researchChemotherapyBiologyInternal medicineCell biologyStem cellTranscription factorBiochemistryGeneCancer-related cognitive impairment studiesGlioma Diagnosis and TreatmentBrain Metastases and Treatment
Adenosine A <sub>2A</sub> receptor blockade prevents cisplatin-induced impairments in neurogenesis and cognitive function | Litcius